IRWD Q1 2025 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$629M

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$41M-45.1% YoY

Gross Profit

$14M33.3% margin

Operating Income

-$29M-70.7% margin

Net Income

-$37M-90.9% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

-54.6%

Cash Flow

Operating Cash Flow

$20M

Free Cash Flow

$20M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$327M

Total Liabilities

$661M

Stockholders' Equity

-$334M

Cash & Equivalents

$108M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$75M	-45.1%
Gross Profit	$14M	$49M	-72.1%
Operating Income	-$29M	$11M	-364.1%
Net Income	-$37M	-$4M	-798.3%

Revenue Segments

Royalty

$800,00068%

Collaborative arrangement, collaboration and license agreements

$373,00032%

Geographic Segments

North America

$39M98%

Europe and Other

$811,0002%